13 Aug
2021

$235 million CAFC decision creates confusion around skinny-label generics, says dissenting judge

The Federal Circuit’s second ruling in the carvedilol dispute between Teva and GSK, though less damaging to skinny-label generics than its first decision, leaves significant questions unanswered.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth